NewsDr. Lal PathLabs Board Meeting Set for January 30, 2026 to Review Q3FY26 Results and Consider Third Interim DividendDr. Lal PathLabs Board Meeting Set for January 30, 2026 to Review Q3FY26 Results and Consider Third Interim Dividend
Dr. Lal PathLabs Limited has scheduled a board meeting for January 30, 2026, to consider Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The board will also evaluate declaring a third interim dividend for FY2025-26. This follows an earlier December 29, 2025 intimation and maintains regulatory compliance with both NSE and BSE disclosure requirements.
*this image is generated using AI for illustrative purposes only.
Dr. Lal PathLabs Limited has informed stock exchanges about an upcoming board meeting scheduled for January 30, 2026, where directors will review the company's third quarter performance and consider dividend distribution to shareholders.
Board Meeting Agenda
The board meeting will address two primary matters for the diagnostic services company. Directors will consider and approve the unaudited financial results for both standalone and consolidated operations covering the quarter and nine months ended December 31, 2025.
| Meeting Details: | Information |
|---|---|
| Date: | January 30, 2026 |
| Purpose: | Q3FY26 Results & Dividend Consideration |
| Results Period: | Quarter & Nine Months ended December 31, 2025 |
| Financial Statements: | Unaudited Standalone & Consolidated |
Dividend Consideration
The board will also deliberate on the declaration of a third interim dividend on equity shares for the financial year 2025-26. The company has indicated that the dividend declaration remains subject to board approval and may not be finalized depending on various factors considered during the meeting.
Regulatory Compliance
Dr. Lal PathLabs submitted this intimation to both the National Stock Exchange of India Limited and BSE Limited on January 23, 2026. The communication serves as a continuation of an earlier intimation dated December 29, 2025, which initially announced the board meeting for Q3FY26 results consideration.
| Exchange Details: | Information |
|---|---|
| NSE Symbol: | LALPATHLAB |
| BSE Scrip Code: | 539524 |
| Intimation Date: | January 23, 2026 |
| Previous Intimation: | December 29, 2025 |
The announcement was signed by Vinay Gujral, Company Secretary and Compliance Officer, ensuring proper regulatory disclosure requirements are met ahead of the scheduled board meeting.
Historical Stock Returns for Dr. Lal Path Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.92% | -7.25% | -3.70% | +30.29% | +17.55% | -1.17% |
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
